Inozyme Pharma, Inc. (INZY) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Boston, MA, United States. The current CEO is Douglas A. Treco.
INZY has IPO date of 2020-07-24, 67 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $258.25M.
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
